Efficacy and Safety of 0.25% Timolol Gel in Enhancing Full Thickness Skin Grafts Healing and Cosmetic Outcomes

Phase 2/3 Terminated 10 enrolled Brigham and Women's Hospital

RandomizedParallel-groupSingle-blindTreatment

Summary

The use of topical beta-blockers, such as 0.25% timolol, in promoting wound healing is currently emerging in the academic literature. The investigators will enroll 82 patients who have their skin cancer surgically removed resulting in the need of a full-thickness skin graft. The objective of this randomized safety study is to determine the safety and efficacy of 0.25% timolol in promoting wound healing in full-thickness skin grafts compared to standard of care.

Timeline

Start: 2019-01-02
Primary completion: 2022-01-10
Completion: 2022-01-10

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Timolol	Other / unclassified	0.25 %	Topical

Indications

No indication recorded.